Novo Nordisk medicine receives U.S. FDA approval for new cardiovascular risk reduction indication: bit.ly/49EGXTw

#PRESS Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction

#PRESS Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023

Today we released our Q4 and FY 2023 financial results. Read the press release: bit.ly/4bkmo04. $NVO

#press #earnings

#PRESS Phase 3a trial successfully completed with once-weekly product demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment in people with type 2 diabetes

#PRESS Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

We strive to drive meaningful change for our employees and the patients we serve. Our goal is to embed #Diversity , #Equity , #Inclusion and #Belonging (DEI&B) into our business, embracing differences to achieve our purpose. Read our 2023 DEI&B Report: bit.ly/40sufDF.

Today, we released our Q3 2023 earnings – read the full financial report here: bit.ly/40pHdCe. $NVO

#PRESS : Today, we announced the FDA approval of our first #RNAi treatment, which is for primary hyperoxaluria type 1 (PH1). Learn more:

#NEWS : Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address innovation gap in #cardiometabolic diseases. #Innovation

#NEWS : Today we announced our 2023 H1 Financial Results

#Press : New data coming out of #ADA2023 .

We are excited to present 26 abstracts showcasing our long-standing innovation and cardiometabolic leadership at the upcoming 83rd Annual Scientific Sessions of the American Diabetes Association (ADA). #ADA2023

#PRESS Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark

#PRESS Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases

We're thrilled to announce a new multi-target collaboration between our #GeneEditing company, Life Edit, with Novo Nordisk! This news is shared in parallel to Novo Nordisk’s equity investment in our $401 million Series D financing. elevate.bio/press-releases…

#PRESS Oral product 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial

Navigating the cost of medication may not always be simple. Explore helpful resources and how you may save on prescriptions at NovoCare.com.

#PRESS : Our financial results for Q1 2023 are out:

#PRESS Novo Nordisk's sales increased by 27% in Danish kroner and by 25% at constant exchange rates to DKK 53.4 billion in the first three months of 2023